Assessments
nausea, anxiety, ’, vomiting or retching, emesis, vomiting, retching
Demographic data were standardly captured at the screening visit. The presence of anxiety, assessed for the purposes of the risk factor analysis, was evaluated on Day 1 prior to chemotherapy as part of the EQ‐5D health‐related quality of life questionnaire.From the start of chemotherapy on day 1 until day 7 (0–144 h), each patient completed a diary, capturing emetic episodes, severity of nausea and concomitant medications taken. An emetic episode was defined as any episode of vomiting or retching or combined vomiting and retching. Severity of nausea was evaluated on a daily basis using a 100‐mm horizontal visual analog scale (VAS). The left end of the scale (0 mm) was labeled as ‘no nausea,’ and the right end of the scale (100 mm) was labeled as ‘extremely strong nausea’.The primary efficacy endpoint in the study was complete response (CR: no emesis and no rescue medication) during the overall (0–120 h) phase following initiation of chemotherapy. In the present post‐hoc analyses of the overall MEC group and in those patients with emetic risk factors, evaluation of complete response was the primary objective. Complete response was assessed during the extended overall phase of 0–144 h and extended delayed (>24–144 h) phase; the previously published acute (0–24 h) phase is included for completeness. Presentation of CR rates during the extended overall phase (0–144 h) relative to the overall phase (0–120 h) (presented in the primary paper